Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability

(2019) Jaegil Kim et al.   EUROPEAN UROLOGY

The Human Microbiota and Prostate Cancer: Friend or Foe?

(2019) Francesco Massari et al.   Cancers

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

(2018) Min Yuen Teo et al.   JOURNAL OF CLINICAL ONCOLOGY

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

(2018) Laurence Zitvogel et al.   SCIENCE

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors

(2018) Tuan Zea Tan et al.   EUROPEAN UROLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

(2018) Markus Eckstein et al.   EUROPEAN JOURNAL OF CANCER

PD-L1 Antibody Comparison in Urothelial Carcinoma

(2018) Maud Rijnders et al.   EUROPEAN UROLOGY

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

(2018) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy in genitourinary malignancies

(2017) Kathan Mehta et al.   Journal of Hematology & Oncology

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

(2017) Thomas Gevaert et al.   SEMINARS IN CANCER BIOLOGY

The Role of Surgical Pathology in Guiding Cancer Immunotherapy

(2016) Scott B. Lovitch et al.   Annual Review of Pathology-Mechanisms of Disease

Immunotargeting and personalized therapies in genitourinary cancers

(2016) Roberta Mazzucchelli et al.   Future Oncology

Immune checkpoint inhibitors side effects and management

(2016) Hampig Raphael Kourie et al.   Immunotherapy

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

The Human Intestinal Microbiome in Health and Disease

(2016) Susan V. Lynch et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of the microbiota in inflammation, carcinogenesis, and cancer therapy

(2014) Amiran Dzutsev et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

The human microbiome: at the interface of health and disease

(2012) Ilseung Cho et al.   NATURE REVIEWS GENETICS

The Application of Ecological Theory Toward an Understanding of the Human Microbiome

(2012) E. K. Costello et al.   SCIENCE